- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
Long-awaited results from the VOICE trial of post-exposure prophylaxis (PrEP) for women in Africa, presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, was not able to show that daily oral tenofovir plus emtricitabine (the drugs in Truvada) could lower the risk of HIV acquisition.
As previously described in a report by Gus Cairns, VOICE randomly assigned more than 5000 women in South Africa, Uganda, and Zimbabwe to use oral tenofovir alone, oral tenofovir plus emtricitabine, tenofovir vaginal gel, or oral or gel placebos, all once-daily.
The oral tenofovir and tenofovir gel arms were previously halted early after interim findings revealed that they would not be able to show a protective effect. The latest results indicate that the same is true for tenofovir/emtricitabine, which researchers attributed to the fact that many women did not use it regularly.
Jeanne Marrazzo from the University of Washington in Seattle summarized the VOICE findings at a CROI HIV prevention press conference on HIV prevention March 4, 2013.
[Jeanne Marrazzo speaks at CROI 2013 press conference, Atlanta, March 4, 2013]
J Marrazzo, G Ramjee, G Nair, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013. Abstract 26LB.